Exelixis
Focus: Exelixis is a California-based oncology-focused biotech company leveraging small-molecule tyrosine kinase inhibitors to address multiple cancer indications. The company operates as a commercial-stage player with a dominant marketed asset and an expanding pipeline in solid tumors.
Profile data last refreshed 13h ago · AI intelligence enriched 2w ago
Open Jobs
56+68 this month
Hot — 93 jobs added in 30d
Net +68 (93 new, 25 removed). Aggressive expansion phase.
Should You Work at Exelixis?
AI assessmentExelixis suits professionals seeking near-term stability and commercial-scale growth in oncology, but pipeline concentration risk and cabozantinib dependency make this a 5–7 year career window rather than a 15-year anchor.
Why Work Here
- Backed by a $1.1B annual Part D revenue stream from CABOMETYX, providing stable cash flow and operational security through 2033 LOE.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$1.1B Part DStable
Peak6.9yr
Flagship multi-indication tyrosine kinase inhibitor generating near-total company revenue and driving all current profitability.
Help build intelligence for Exelixis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.